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and medications were taken from official sources and an institution of national 
reference of oncology services. The safety and effectiveness data were taken from 
the literature and two Colombian cohorts (one retrospective and one prospective) 
with patients older than 15 years. The unit of outcome was the proportion of deaths 
averted. The incremental cost effectiveness ratio (ICER) was estimated, univari-
ate sensitivity and probabilistic analysis were performed. Results: Model results 
indicate that under the scenario of a clinical trial not using factor was a dominated 
alternative (ICER of - 61,753,681 COP per death averted). In contrast, using data from 
the Colombian cohorts, factor was dominated strategy (ICER of - 141,421,622 COP 
for retrospective cohort and prospective cohort -215,449,438 COP). The variable that 
most impacted the outcome was the incidence of febrile neutropenia (12% for the 
clinical trial, 60% retrospective cohort and 83% prospective cohort). The results were 
robust to the probabilistic sensitivity analysis. With the data from the clinical trial 
in 94% of cases using factor was cost effective, while in the Colombian data in 84% 
and 72% of cases (retrospective and prospective cohort respectively) was not cost 
effective to use factor. ConClusions:: With Colombian information the prophy-
lactic use of the factor under chemotherapeutic induction in adults with ALL turns 
out to be not cost-effective. The gap in the results suggests a careful extrapolation 
of information from clinical trials (ideal world) to develop economic evaluations in 
Colombia, and its impact on decision making.
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Cost-EffECtivENEss of full-fiEld digital MaMMograPhy vErsus 
sCrEEN-filM MaMMograPhy iN BrEast CaNCEr sCrEENiNg
Hipolito C., Gallegos V, Hernandez E.
National Center for Health Technology Excellence, Mexico City, Mexico
objeCtives: Analyze the cost-effectiveness of full-field digital mammography (DM) 
compared to the screen-film mammography (SFM) among different age groups of 
Mexican women. Methods: A cost-effective study was developed - from the public 
sector perspective- to estimate the cost per cancer detected by DM vs. SFM in the 
following age groups: 40-49, 50-59 and 60-69 years old. Additional costs and effects 
were estimated by comparing DM against SFM and expressed as incremental cost-
effectiveness ratio (ICER). The outcome was the number of detected cases. Staff 
wages and tests cost (mammography, ultrasound and biopsy) were included. An 
univariate sensitivity analysis was carried out with key variables. Results: DM is 
more expensive and more effective than SFM for breast cancer detection. Using DM 
for 50-59 age group is not cost- effective since it detects fewer cases at a higher cost. 
In the 40-49 age group, the ICER for DM was $318,828 per additional case detected, 
while in the 60-69 the ICER for DM was $255,636. The ICER was sensitive to the lower 
cost of DM. ConClusions: For some age groups, DM is more effective than SFM; 
however, DM cost limits its use in a screening program. Evidence shows, SFM still 
has advantages in detecting breast cancer at an affordable cost. Further research 
taking into consideration social, organizational and staff training issues is important
PCN108
ParaMEtEr valuEs assoCiatEd with thE dEvEloPMENt of a gloBal 
ECoNoMiC ModEl to valuE CoMPaNioN diagNostiCs iN advaNCEd/
MEtastatiC CaNCEr trEatMENt
Lachaine J., Mathurin K., Beauchemin C.
University of Montreal, Montreal, QC, Canada
objeCtives: Many targeted anticancer drugs under development will be used with a 
companion diagnostic. The objective of this study was to define parameter values that 
will be included in a global model estimating the cost-effectiveness of a companion 
diagnostic in advanced/metastatic cancer treatment. Methods: As the model will 
be generic to allow its use in the most common cancers in Canada (breast, prostate, 
lung, colorectal, bladder, cervical, non-Hodgkin’s lymphoma), specific parameters 
for each cancer of interest (including health state utilities and costs associated with 
cancer management) were considered. Consequently, a literature review was con-
ducted using electronic databases from January 2000 until September 2013 to extract 
these parameters in economic models in advanced/metastatic cancer available. Cross-
references studies and governmental publications were also consulted. Canadian 
costs and disutilities associated with any grade 3-4 treatment-related adverse events 
(AEs) were also obtained. Results: Lung cancer was associated with the highest 
inpatient cost ($CAN19,875/stay of 9.9 days on average), while patients with prostate 
cancer incurred the highest cost associated with emergency visits ($CAN721.55/case). 
Costs associated with end-of-life care were similar among cancer types, with an aver-
age cost of $CAN31,081/case and 152 days of end-of-life care. Thirty-nine AEs were 
retrieved. Costs associated with management of AEs were up to $CAN71,967/case 
(development of secondary malign neoplasm), with an average cost of $CAN7,717/
event. Disutilities associated with the incidence of AEs were up to 0.465 (hip fracture), 
with an average utility loss of 0.135. Lung cancer presented the worst health state 
utility values (0.611 in pre-progression and 0.441 in progression). ConClusions: 
Although the model structure and key elements required to assess the cost-effec-
tiveness of a companion diagnostic can be generalized to different cancer types, this 
study suggests that parameter values should be specific to the cancer of interest.
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CaN NExt gENEratioN sEquENCiNg savE livEs aNd ProvidE a good 
ECoNoMiC valuE iN ColoN CaNCEr PrEvENtioN?
Gallego C.J.1, Shirts B.1, Garrison L.2, Jarvik G.1, Veenstra D.L.3
1University of Washington, Seattle, WA, USA, 2University of Washington School of Pharmacy, 
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objeCtives: Screening of all patients diagnosed with colorectal cancer for Lynch 
syndrome using a staged testing procedure is currently recommended by Evaluation 
of Genomic Applications in Practice and Prevention (EGAPP) guidelines. Next gen-
eration sequencing (NGS) is a disruptive technology that likely offers improved 
outcomes, but its value is uncertain. The goal of this study was to evaluate the 
cost effectiveness of NGS vs. tumor tissue testing for universal testing of patients 
with colorectal cancer (CRC) to detect relatives with Lynch syndrome. Methods: 
adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was 
calculated. As Japanese Ministry of Health, Labour and Welfare has not yet approved 
abiraterone due to the delay in development, the drug cost was estimated based 
on prices in four other countries. In the present study, resource use was estimated 
using a Japanese claim data set with 2000 claim data of prostate cancer patients 
from January 2005 to March 2013. Both cost and outcomes were discounted at a 
2% annual rate. Results: The result of this study revealed that abiraterone plus 
prednisolone indicated higher QALYs than prednisolone alone. In the base-case 
analysis, ICER for abiraterone plus prednisolone exceeded JPY 17 million (roughly 
EUR 120,000) per QALY gained. One-way sensitivity analysis for the price of abira-
terone influenced ICER (JYP 12.5 - 21 million). ConClusions: The present study 
suggested that the ICER is more than JPY 10 million. Further deliberate discussion 
on cost-effectiveness of abiraterone in Japan is needed to consider the Japanese 
price and clinical outcomes.
PCN104
usE of Psa sloPE to guidE adjuvaNt radiothEraPy iN Post-
ProstatECtoMy ProstatE CaNCEr has PotENtial to BE Cost EffECtivE
Reed S.D.1, Biehn Stewart S.2, Scales C.D.2, Moul J.W.2
1Duke Clinical Research Institute, Durham, NC, USA, 2Duke University School of Medicine, 
Durham, NC, USA
objeCtives: NADiA ProsVue is a prognostic system developed to identify men at 
lower risk for clinical recurrence of prostate cancer following radical prostatec-
tomy, as indicated by a prostate-specific antigen (PSA) slope < = 2 pg/mL/month. 
We evaluated the potential cost-effectiveness of using the prognostic system to 
guide adjuvant radiotherapy (ART) in men considered to be at intermediate- or 
high-risk for recurrence based on the CAPRA-S nomogram. Methods: We devel-
oped a decision analytic model consisting of a decision tree to stratify men into 
risk groups and a state transition model to generate long-term costs and outcomes. 
We derived model parameters using patient-level data from the product’s 510(k) 
registration study, the medical literature and other sources. We conducted probabil-
istic, one-way and two-way sensitivity analyses to examine the cost-effectiveness 
of the system (i.e. with PSA slope findings) versus standard care (i.e. without PSA 
slope findings). Results: The cost-effectiveness of a PSA slope-guided strategy 
varied widely due to small differences in QALYs at 10 years. Assuming that 20% of 
men in the intermediate-risk CAPRA-S group receive ART with standard care, the 
incremental cost-effectiveness ratio (ICER) is less than $50,000 per QALY when use 
of ART is less than 8.2% among men with PSA slopes < = 2 pg/mL/month. Assuming 
that 40% in the high-risk CAPRA-S group receive ART with standard care, ART would 
have to decrease to at least 11.5% among men with PSA slopes < = 2 pg/mL/month to 
achieve an ICER less $50,000 per QALY. ICERS were also sensitive to varying the costs 
of the prognostic system and ART, varying the benefits of salvage therapy and utility 
weights for ART toxicities. ConClusions: The ProsVue system has the potential 
to be cost effective, but its value will be dependent on the magnitude of reduction 
in ART among men identified as having a low risk of recurrence.
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Cost-EffECtivENEss of CEtuxiMaB as first-liNE trEatMENt for 
MEtastatiC ColorECtal CaNCEr iN thE uNitEd statEs
Ortendahl J.D.1, Bentley T.G.1, Anene A.M.1, Purdum A.G.2, Bolinder B.2
1Partnership for Health Analytic Research, LLC, Beverly HIlls, CA, USA, 2Bristol-Myers Squibb, 
Plainsboro Township, NJ, USA
objeCtives: To evaluate the clinical and economic tradeoffs associated with 
FOLFIRI + either cetuximab or bevacizumab as 1st-line therapies among KRAS wild 
type (WT) metastatic colorectal cancer (mCRC) patients, through a cost-effective-
ness analysis incorporating Phase III FIRE3 clinical trial data. Methods: A deter-
ministic cost-effectiveness model was developed to project lifetime survival and 
costs of FOLFIRI used with either cetuximab or bevacizumab. A cohort of 1st-line 
patients faced risks of adverse events, progression to 2nd-line treatment, or eligibility 
for curative liver resection. Clinical trial data, published literature, and publicly avail-
able databases were used to estimate model inputs. Incremental cost-effectiveness 
ratios (ICERs) were calculated as 2013 US$ per life year (LY) and per quality-adjusted 
life year (QALY). We conducted a scenario analysis to analyze the subset of RAS WT 
patients. The impact of parameter uncertainty was also evaluated with one-way and 
probabilistic sensitivity analyses. Results: Compared with 1st-line bevacizumab 
KRAS WT patients, those treated with cetuximab gained an additional 5.7 months of 
life (42.9 vs. 37.2) at a cost of $46,301 ($280,933 vs. $234,632), for an ICER of $97,297/LY 
($122,704/QALY). The benefits of cetuximab were also greater for RAS WT patients, 
for whom the ICER was $77,380/LY ($99,636/QALY). Treatment with cetuximab would 
be cost effective 53.6% of the time, given a willingness to pay threshold of $100,000/
LY. Results were most sensitive to changes in 1st-line survival, treatment duration, 
and product acquisition costs. ConClusions: Treatment with cetuximab + FOLFIRI 
in 1st-line mCRC patients may improve health outcomes and use financial resources 
more efficiently than bevacizumab + FOLFIRI, given current societal standards. This 
information can be useful to clinicians, payers, and policy makers in making treat-
ment and resource allocation decisions for KRAS WT and RAS WT mCRC patients.
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Cost-EffECtivENEss of ProPhylaCtiC usE of filgrastiM iN adults 
with aCutE lEukEMia lyMPhoBlastiC ColoMBia
Casadiego E.J.1, Diaz Rojas J.A.2, Bermudez C.3, Prieto-Martinez V.4, Urrego Novoa J.R.5
1CENTRO DERMATOLOGICO, Colombia, 2Universidad Nacional de Colombia, Bogota D,C., 
Colombia, 3Instituto Nacional de Cancerología, 4Universidad Nacional de Colombia, Bogotá, 
Colombia, 5Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia
objeCtives: To determine the cost-effectiveness of prophylactic administration 
of Filgrastim compared with no use, during the induction phase of chemother-
apy in adults with Acute Lymphoblastic Leukemia (ALL) in the Colombian con-
text. Methods: A decision tree with a time horizon of 30 days is built under the 
third-party payer perspective including only direct costs. The costs of procedures 
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bACkgRound: In Mexico breast cancer reported an incidence of 13,939 cases 
and 5,217 mortality cases in 2008. Between 40-50% of those cases are diagnosed 
in stages III and IV. objeCtives: The aim of this study was to assess a cost-effec-
tiveness analysis for the use of fulvestrant 500mg as a therapy for postmenopausal 
women with locally advanced or metastatic breast cancer with ER+ receptor and 
prior progression on endocrine therapy, from Public Health Sector perspective in 
Mexico. Methods: A cost-effectiveness analysis was performed using a Markov 
model with a time horizon of 1 and 5 years according to a prior economic evalua-
tion and based on the results from CONFIRM study. Two cohorts of treatment were 
compared; Cohort A contemplates the addition of fulvestrant to the standard treat-
ment and Cohort B the standard treatment. The effectiveness was measured as Life 
years Gained (LY). The use of resources was determined from the clinical practice 
in Mexico and costs were obtained from institutional sources. Results: The ICER 
per LY for 1 year time horizon was $9,609 for Cohort A versus Cohort B. The fifth 
year implies an ICER of $6,581, being in both cases an ICER below the willingness 
to pay in Mexico (1 GDP: $10,000USD). ConClusions: Based on the findings the 
use of fulvestrant is a cost-effective strategy that provides a longer period of stable 
disease, an improvement in LY, diminish the use of chemotherapy and optimize 
institutional resources.
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assEssMENt Cost-EffECtivENEss of PEgfilgrastiM aNd filgrastiM iN 
PEdiatriC PatiENts with solid tuMors
Medina Barajas F.P.1, Sánchez Zubieta F.2, Islas Carbajal M.C.3, Pardo Zepeda M.1,  
Ramírez Urenda X.2, Rincón Sánchez A.R.3
1Universidad de Guadalajara, Guadalajara, Mexico, 2Hospital Civil de Guadalajara, Guadalajara, 
Mexico, 3CUCS, Universidad de Guadalajara, Guadalajara, Mexico
objeCtives: Evaluate the cost- effectiveness of pegfilgrastim compared with fil-
grastim relationship in preventing febrile neutropenia in pediatric patients with 
solid tumors. Methods: Retrospective cohort study from 2012 to 2014, and was 
made micro-cost technic. Records of pediatric patients diagnosed with solid tumors 
receiving pegfilgrastim and filgrastim post-chemotherapy for prevention of febrile 
neutropenia were evaluated. Febrile neutropenia is considered as an event with 
absolute neutrophil count less than 1000 cells per milliliter blood and fever ≤ 38.2°C. 
This study adheres to the principles of the Declaration of Helsinki, followed good 
clinical practices and has been approved by Hospital bioethics committee. Results: 
120 and 152 cases of pegfilgrastim and filgrastim respectively were included. The 
mean age was 9 years, 63 % male and 47 % female. The absolute neutrophil count 
was 6,204 with pegfilgrastim and filgrastim 2,332. Filgrastim was more effective 
cost $ 1195 pesos per thousand neutrophils, in cases where lower doses were 
administered to 200 micrograms per maximum 7 days. The cost-effectiveness of 
pegfilgrastim was $ 2,484 per thousand neutrophils, reaching a cost effective advan-
tage in cases of patients over 40 kilos would require 7 to 14 doses of filgrastim. No 
significant differences in the effectiveness of pegfilgrastim and filgrastim in post-
chemotherapy preventing neutropenia were observed. ConClusions: Filgrastim 
maintains effective cost advantage over pegfilgrastim when the dose is less than 
200 micrograms in a treatment period of at least 7 days
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a raNdoMizEd CliNiCal study to EvaluatE EffECts of 
EiCosaPENtaENoiC aCid ENriChEd oral NutritioNal suPPlEMENt 
aloNg with radio-ChEMothEraPy iN PatiENts with ColorECtal 
CarCiNoMa: a Cost-EffECtivENEss aNalysis
Berktas M.1, Kilic D.2, Ozcagli T.G.3, Sencan N.1
1Yeditepe University PEPIRC, Istanbul, Turkey, 2Gazi University, Ankara, Turkey, 3Abbott Nutrition, 
Istanbul, Turkey
objeCtives: A randomized clinical study compare effects of pre-operative eicosap-
entaenoic acid enriched oral nutritional supplement (EPA-ONS) along with 5-weeks 
radio-chemotherapy to 5-weeks radio-chemotherapy only on survival and quality 
of life and safety had been completed and the results were published elsewhere. 
This abstract aimed evaluate cost effectiveness of 5-week EPA ONS usage com-
pared to no nutritional supplement in terms of survival. Methods: A total 80 colo-
rectal carcinoma patients had been randomized to 5-week radio-chemotherapy 
(FUFA+EBRT)+EPA ONS (2 package per day) or radio-chemotherapy (FUFA+EBRT) 
only equally by stratifying age, gender, nutritional status and radiotherapy method. 
In study time horizon, survival was evaluated by Kaplan Maier estimator and expo-
nential parametric regression model (best fitting model based on AIC-BIC) was used 
to extrapolate 10-year survival. Since patients’ characteristics, treatment modalities 
and other procedures were reported to be similar among groups, only cost of EPA 
ONS was taken into cost-analysis which is prepared from perspective of reimburse-
ment institute in Turkey. Results: Mean (95% confidence interval) survival time 
was 6.8(6.3-7.3) and 5.5(4.6-6.4) years in EPA-ONS + radio-chemotherapy and radio-
chemotherapy only groups, respectively. Five week EPA-ONS costs 224.6 USD/per 
patient. Incremental cost effectiveness ratio (ICER) for in study period was 234.4 
USD per life-year gained; when 10-year survival model was used ICER was 97.5 USD 
per life-year gained. ConClusions: Survival analysis revealed that preoperative 
EPA-ONS usage along with radio-chemotherapy prolonged overall survival. EPA-
ONS appears to be a cost-effective concomitant treatment of radio-chemotherapy 
in patient with colorectal carcinoma.
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ProjECtiNg thE PotENtial PuBliC hEalth iMPaCt of a 9-valENt hPv 
vaCCiNE iN jaPaN
Weiss T1, Pillsbury M.2, Abe M.3, Sato M.3, Yamabe K.4
1Merck & Co, Inc., West Point, PA, USA, 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 
USA, 3MSD.K.K. Japan, Tokyo, Japan, 4MSD.K.K. & HTA and Public Policy, Graduate School of 
Public Policy, The University of Tokyo, Tokyo, Japan
objeCtives: To estimate the potential public health impact of a 9-valent HPV 
(human papillomavirus) vaccine (HPV9) in Japan in preventing HPV-related dis-
We developed a decision model comparing IHC/MSI tumor tissue testing (IHC/
MSI), followed by targeted sequencing of the suspected gene to two hypothetical 
universal screening strategies: (1) NGS as a reflex test to IHC/MSI testing if these 
tests suggest a protein abnormality; (3) use of a NGS gene panel in all patients 
with CRC. Outcomes measured were life-years gained, quality adjusted life years 
(QALY) gained, and costs, Sensitivity analyses were conducted to assess uncer-
tainty. Results: Compared to the reference strategy, the price per QALY gained 
was $196,000 for universal NGS gene panel testing. When using NGS gene panel as 
a reflex strategy to abnormal IHC/MSI, the price per QALY was $71,000. The most 
influential variables in the one-way sensitivity analysis were the number of relatives 
tested, the prevalence of Lynch syndrome in CRC patients and the cost of CRC sur-
veillance in relatives with Lynch syndrome detected. ConClusions: Use of NGS in 
all colorectal cancer patients to detect inherited cancer and inform family members 
is unlikely to be cost-effective despite the lower per base pair sequencing cost of 
NGS. However, NGS may be cost-effective when used as a complement to tumor-
tissue testing strategies. Further studies are needed to validate these findings.
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aN outCoMEs ModEl for high-risk NoN-MusClE-iNvasivE BladdEr 
CaNCEr trEatMENt oPtioNs
Ramamohan V.1, Mladsi D.M.2, Boey W.3, Pozzi R.4, Kaye J.A.5
1RTI Health Solutions, Durham, NC, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 
3Telormedix, Bioggio, Switzerland, 4Telormedix SA, Bioggio, Switzerland, 5RTI Health Solutions, 
Waltham, MA, USA
objeCtives: High-risk, non-muscle-invasive bladder cancer (NMIBC) is heteroge-
neous in its presentation, resulting in patient subpopulations with diverse treat-
ment options. A comprehensive model estimating costs and health outcomes 
with various NMIBC treatment strategies is needed for diverse patient subpopula-
tions. Methods: A Markov model simulating patient outcomes was developed 
based on published treatment guidelines. Health states encompass high-risk NMIBC, 
tumor-free, muscle-invasive progression (MIP), and metastasis. Four patient popula-
tions were considered: (1) high-risk T1 or Ta tumors; (2) Carcinoma in situ (Cis) only; 
(3) high-risk T1/Ta tumors with concomitant Cis; (4) general NMIBC population with 
high-risk T1/Ta tumors and/or Cis. Treatment options include trans-urethral resec-
tion (TUR) and adjuvant intravesical bacillus Calmette-Guérin (BCG), mitomycin C 
(MMC) or valrubicin for populations (1), (3) and (4), or intravesical treatment alone for 
population (2). The model assesses treatments as first- or second-line, or as alterna-
tives for patients intolerant of or refractory to other treatment. Radical cystectomy 
is performed after MIP or repeated treatment failure. Response (in patients with Cis) 
and recurrence rates and percentages of BCG-intolerant/refractory patients were 
estimated from the literature. Costs were obtained from publicly available sources. 
The model was validated against published epidemiology and cost data. Results: 
The lifetime cost per person of treating high-risk T1/Ta patients with BCG was within 
20% of costs estimated in published economic models. The lifetime cost per person 
of treating BCG-intolerant/refractory Cis patients with valrubicin was estimated to 
be 45% higher than for cystectomy. Adverse event costs for the general high-risk 
NMIBC population treated with BCG account for 17% of the total treatment cost com-
pared with 5% for MMC. Approximately 40% and 15% of patients treated with BCG 
eventually undergo cystectomy and MIP, respectively. ConClusions: This validated 
model can be used to estimate costs and health outcomes associated with existing 
treatment strategies as well as the cost-effectiveness of novel intravesical therapies.
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Cost-EffECtivENEss aNalysis of BEvaCizuMaB iN CoMBiNatioN with 
PC rEgiMEN vErsus PC rEgiMEN iN NoN-sMall CEll luNg CaNCEr 
trEatMENt
Nguyen T.T.T., Tran T.T.H.
University of Medicine and Pharmacy in HCMC, HCMC, Vietnam
objeCtives: Fabulous advance in treatment of NSCLC has been made since the late 
1990s, remarkably with the development of targeted drugs such as bevacizumab 
(BEV). Despite of the proved effectiveness and safety of BEV in treatment of NSCLC, 
the high price of drug caused obstacles in using drugs in clinical practice. The cost-
effectiveness of BEV has been evaluated in many countries. However until now there 
isn’t any relevant study has been evaluated. This is the aim of this study. Methods: 
A Markov model has been developed to evaluate the cost-effectiveness of beva-
cizumab in treatment of NSCLC with 3 Markov stages, including stable disease, 
progressive disease and death. The model has a cycle length of 1 year with the time 
horizon of life time. The population of 1000 patients patients, entering the model 
in the SD state, has been evaluated to assess the cost of effectiveness of different 
treatment regimens. The transition rates have been retrieved from clinical trials. The 
prices of drugs and medical services have been retrieved from relevant price-lists of 
major hospitals in Vietnam. The sensitivity analysis has been conducted to evaluate 
the sensitivity of model. Results: The cost of BCP and PC regimen for treatment 
of NSCLC accounts for 5,979,573,560 VND and 992,767,115 with the QALY of 10.43 
and 7.24, respectively. The CER of BCP regimens for treatment of NCSLC accounts 
for 573,199,170 VND, which is around 4 times higher than that of PC regimen. The 
ICER of BCP regimen versus PC regimen in treatment of NSCLC accounts for around 
1.56 billion VND, which is around 20 times higher than the willingness-to-pay of 
Vietnam (60 million VND). ConClusions: Due to the high cost of drug, combina-
tion of bevacizumab in the PC regimen in treatment of NSCLC is considered not 
cost-effectiven in Vietnam.
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ECoNoMiC EvaluatioN of fulvEstraNt 500Mg for thE trEatMENt of 
PostMENoPausal woMEN with advaNCEd BrEast CaNCEr who havE 
ProgrEssEd oN ENdoCriNE thEraPy
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